Janssen presented four-year data on Stelara in adults with moderately to severely active ulcerative colitis.
Janssen presented four-year long-term extension data of Stelara (ustekinumab) in adults with moderate to severe ulcerative colitis. Among the patients who achieved clinical response in the induction phase, 64.9% achieved symptomatic remission after 44 weeks of maintenance. 55.2% of patients had remission at week 200, among which 96.4% avoided corticosteroids.
Among the patients who received Stelara as the first biologic, 71.8% had symptomatic remission after 44 weeks of maintenance treatment, and 67.2% had symptomatic remission at week 200.
The UNIFI LTE study also showed that patients receiving corticosteroids at the baseline of maintenance could avoid corticosteroids by week 200.
Janssen presented the combination data of Simponi and Tremfya in moderate to severe ulcerative colitis patients.
Janssen presented the Phase 2a study, evaluating the efficacy of the Simponi (golimumab) plus Tremfya (guselkumab) combination in patients with moderate to severe ulcerative colitis.
Simponi and Tremfya combination was administered as induction treatment for 12 weeks, followed by maintenance treatment with Tremfya resulted in higher clinical remission of 47.9% at week 38 compared to Tremfya monotherapy (31%) or Simponi monotherapy (20.8%).
Currently, Tremfya as monotherapy or in combination with Simponi was not approved for ulcerative colitis and is under investigation.
Janssen announced that VEGA is the first study that evaluates the combination of interleukin inhibitor (Tremfya) and TNF inhibitor (Simponi).
Dupixent demonstrated significant histological remission of eosinophilic esophagitis in children.
Sanofi and Regeneron Pharmaceutical presented Dupixent (dupilumab) late-stage data in children with eosinophilic esophagitis. 68% of patients on a higher dose and 58% of children on a lower dose achieved clinical remission versus 3% on placebo. There was an improvement in endoscopic abnormalities in children treated with a higher dose; abnormal endoscopic findings were reduced by 3.5 points versus an increase of 0.3 points in children on the placebo.
In May 2022, the US FDA approved Dupixent for eosinophilic esophagitis in 12 years and older.
There are 21,000 children currently being treated with eosinophilic esophagitis, and nearly 9,000 patients do not show a satisfactory response to the current standard of care.